Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of REGN9933 in Healthy Adults
NCT05102136Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2021
- Primary completion
- Apr 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of amrecibart in venous thromboembolism (VTE) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Incidence and severity of treatment emergent adverse events at 36 days. Started Oct 2021; status: completed.
02
Drugs
amrecibart
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT05102136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05102136.